Skip to content

Xencor XNCR Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$7.19M+20.5%
Zymeworks logo
ZymeworksZYME
$178.79M+13,486%
Amgen logo
AmgenAMGN
Summit Therapeutics logo
Summit TherapeuticsSMMT

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.09B+79.8%
Enterprise value$1.25B+58.6%
P/S11.2×+6.4×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's cash provided by (used in) financing activity, including discontinued operation?
Xencor (XNCR) reported cash provided by (used in) financing activity, including discontinued operation of $950K in Q1 2026.
How has Xencor's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
Xencor's cash provided by (used in) financing activity, including discontinued operation decreased by 23.9% year-over-year, from $1.25M to $950K.
What is the long-term trend for Xencor's cash provided by (used in) financing activity, including discontinued operation?
Over 4 years (2021 to 2025), Xencor's cash provided by (used in) financing activity, including discontinued operation has grown at a -33.9% compound annual growth rate (CAGR), from $43.04M to $8.23M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.